Wells Fargo analyst David Maris noted Valeant's announcement earlier today that the company has decided to raise prices by 2% to 9% on a broad range of products. He believes the price increases are a result of the company taking "a sobering look at disappointing prescription trends" and continues to contend that consensus estimates for Valeant in 2017 are too high. The analyst, who has kept an Underperform rating on Valeant shares since starting coverage of the stock in February, said the company's "story is the same as it has been, and the only change is in how it is being told."